{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T05:02:16Z","timestamp":1792040536723,"version":"4.4.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"1-2","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,12]],"date-time":"2022-02-12T00:00:00Z","timestamp":1644624000000},"content-version":"am","delay-in-days":407,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revue Neurologique"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.neurol.2020.04.029","type":"journal-article","created":{"date-parts":[[2020,7,24]],"date-time":"2020-07-24T08:13:15Z","timestamp":1595578395000},"page":"100-106","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Should we prevent thrombosis related to intravenous immunoglobulin infusions with systematic anticoagulant prophylaxis?"],"prefix":"10.1016","volume":"177","author":[{"given":"R.","family":"Arcani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.-M.","family":"Grapperon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Venton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Suchon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Verschueren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Bas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Salort-Campana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Attarian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Delmont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neurol.2020.04.029_bib0195","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/S0755-4982(06)74668-1","article-title":"Immunoglobulines intraveineuses: indications actuelles et perspectives","volume":"35","author":"Mouthon","year":"2006","journal-title":"Presse M\u00e9dicale"},{"issue":"2","key":"10.1016\/j.neurol.2020.04.029_bib0200","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/S1474-4422(07)70329-0","article-title":"Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial","volume":"7","author":"Hughes","year":"2008","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.neurol.2020.04.029_bib0205","first-page":"CD002277","article-title":"Intravenous immunoglobulin for myasthenia gravis","volume":"12","author":"Gajdos","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.neurol.2020.04.029_bib0210","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1212\/WNL.0b013e3181f0738e","article-title":"Correlates of outcome and response to IVIg in 88 patients with multifocal motor neuropathy","volume":"75","author":"Cats","year":"2010","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2020.04.029_bib0215","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1212\/01.WNL.0000074394.15882.83","article-title":"Strokes, thromboembolic events, and IVIg: rare incidents blemish an excellent safety record","volume":"60","author":"Dalakas","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2020.04.029_bib0220","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1002\/ajh.2830440321","article-title":"Deleterious effects of intravenous immunoglobulin in a patient with thrombotic thrombocytopenic purpura","volume":"44","author":"Durand","year":"1993","journal-title":"Am J Hematol"},{"key":"10.1016\/j.neurol.2020.04.029_bib0225","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1111\/j.1365-2133.2006.07390.x","article-title":"Intravenous immunoglobulin-associated arterial and venous thrombosis; report of a series and review of the literature","volume":"155","author":"Marie","year":"2006","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.neurol.2020.04.029_bib0230","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.revmed.2016.10.390","article-title":"[Management of adverse effects related to human immunoglobulin therapy: Recommendations for clinical practice]","volume":"38","author":"Marie","year":"2017","journal-title":"Rev Med Interne"},{"key":"10.1016\/j.neurol.2020.04.029_bib0235","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1046\/j.1468-1331.2003.00542.x","article-title":"Thrombosis complicating high dose intravenous immunoglobulin: report of three cases and review of the literature","volume":"10","author":"Zaidan","year":"2003","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.neurol.2020.04.029_bib0240","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1212\/WNL.47.3.674","article-title":"Complications of intravenous immune globulin treatment in neurologic disease","volume":"47","author":"Brannagan","year":"1996","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2020.04.029_bib0245","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1212\/WNL.44.2.223","article-title":"High-dose intravenous immunoglobulin and serum viscosity: risk of precipitating thromboembolic events","volume":"44","author":"Dalakas","year":"1994","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2020.04.029_bib0250","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1007\/s00415-003-1085-1","article-title":"Side effects of intravenous immunoglobulins in neurological autoimmune disorders--a prospective study","volume":"250","author":"Stangel","year":"2003","journal-title":"J Neurol"},{"key":"10.1016\/j.neurol.2020.04.029_bib0255","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.jns.2011.05.035","article-title":"Thromboembolic complications of intravenous immunoglobulin therapy in patients with neuropathy: a two-year study","volume":"308","author":"Rajabally","year":"2011","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.neurol.2020.04.029_bib0260","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3389\/fimmu.2015.00011","article-title":"On the dark side of therapies with immunoglobulin concentrates: the adverse events","volume":"6","author":"Sp\u00e4th","year":"2015","journal-title":"Front Immunol"},{"key":"10.1016\/j.neurol.2020.04.029_bib0265","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1159\/000081465","article-title":"Thromboembolic complications of intravenous immunoglobulin treatment","volume":"52","author":"Vucic","year":"2004","journal-title":"Eur Neurol"},{"key":"10.1016\/j.neurol.2020.04.029_bib0270","first-page":"962","article-title":"Single high-dose intravenous immunoglobulin therapy for kawasaki disease increases plasma viscosity","volume":"69","author":"Baba","year":"2005","journal-title":"Circ J Off J Jpn Circ Soc"},{"key":"10.1016\/j.neurol.2020.04.029_bib0275","first-page":"775","article-title":"Intravenous immunoglobulin, blood viscosity and myocardial infarction","volume":"13","author":"Fisman","year":"1997","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.neurol.2020.04.029_bib0280","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1002\/ajh.10325","article-title":"Intravenous immunoglobulin therapy results in post-infusional hyperproteinemia, increased serum viscosity, and pseudohyponatremia","volume":"73","author":"Steinberger","year":"2003","journal-title":"Am J Hematol"},{"key":"10.1016\/j.neurol.2020.04.029_bib0285","first-page":"617","article-title":"Anti-red blood cell antibodies, free light chains, and antiphospholipid antibodies in intravenous immunoglobulin preparations","volume":"15","author":"Sakem","year":"2013","journal-title":"Isr Med Assoc J IMAJ"},{"key":"10.1016\/j.neurol.2020.04.029_bib0290","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1177\/000331970205300117","article-title":"Intravenous immunoglobulin-related acute coronary syndrome and coronary angiography in idiopathic thrombocytopenic purpura--a case report and literature review","volume":"53","author":"Crouch","year":"2002","journal-title":"Angiology"},{"key":"10.1016\/j.neurol.2020.04.029_bib0295","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1055\/s-0032-1325616","article-title":"Iatrogenic hyperviscosity and thrombosis","volume":"38","author":"Baskurt","year":"2012","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.neurol.2020.04.029_bib0300","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1002\/1096-8652(200010)65:2<177::AID-AJH17>3.0.CO;2-K","article-title":"Acute myocardial infarction during treatment with intravenous immunoglobulin for idiopathic thrombocytopenic purpura (ITP)","volume":"65","author":"Paolini","year":"2000","journal-title":"Am J Hematol"},{"key":"10.1016\/j.neurol.2020.04.029_bib0305","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1159\/000008040","article-title":"High-dose intravenous immunoglobulin treatment and cerebral vasospasm: A possible mechanism of ischemic encephalopathy?","volume":"41","author":"Sztajzel","year":"1999","journal-title":"Eur Neurol"},{"key":"10.1016\/j.neurol.2020.04.029_bib0310","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1111\/j.1399-0039.1992.tb01910.x","article-title":"Soluble HLA class I and class II concentrations in commercial immunoglobulin preparations","volume":"39","author":"Grosse-Wilde","year":"1992","journal-title":"Tissue Antigens"},{"key":"10.1016\/j.neurol.2020.04.029_bib0315","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1111\/j.1440-1797.2010.01399.x","article-title":"Slow and steady. Reducing thrombotic events in renal transplant recipients treated with IVIg for antibody-mediated rejection","volume":"16","author":"Huang","year":"2011","journal-title":"Nephrol Carlton Vic"},{"key":"10.1016\/j.neurol.2020.04.029_bib0320","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1136\/bmj.39609.449676.25","article-title":"Predicting cardiovascular risk in England and Wales: prospective derivation and validation of QRISK2","volume":"336","author":"Hippisley-Cox","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.neurol.2020.04.029_bib0325","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1212\/WNL.0b013e318208824b","article-title":"Rasch-built Overall Disability Scale (R-ODS) for immune-mediated peripheral neuropathies","volume":"76","author":"van Nes","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2020.04.029_bib0330","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1136\/jnnp.2005.081547","article-title":"A modified peripheral neuropathy scale: the Overall Neuropathy Limitations Scale","volume":"77","author":"Graham","year":"2006","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.neurol.2020.04.029_bib0335","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1002\/ana.410410615","article-title":"Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis. Myasthenia Gravis Clinical Study Group","volume":"41","author":"Gajdos","year":"1997","journal-title":"Ann Neurol"},{"key":"10.1016\/j.neurol.2020.04.029_bib0340","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.jviscsurg.2016.04.013","article-title":"Medical complications following splenectomy","volume":"153","author":"Buzel\u00e9","year":"2016","journal-title":"J Visc Surg"},{"key":"10.1016\/j.neurol.2020.04.029_bib0345","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.surg.2015.06.014","article-title":"Splenectomy is associated with hypercoagulable thrombelastography values and increased risk of thromboembolism","volume":"158","author":"Pommerening","year":"2015","journal-title":"Surgery"},{"key":"10.1016\/j.neurol.2020.04.029_bib0350","doi-asserted-by":"crossref","first-page":"e5098","DOI":"10.1097\/MD.0000000000005098","article-title":"Long-term complications of splenectomy in adult immune thrombocytopenia","volume":"95","author":"Thai","year":"2016","journal-title":"Medicine (Baltimore)"},{"issue":"Suppl 1","key":"10.1016\/j.neurol.2020.04.029_bib0355","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/S0960-8966(17)30288-2","article-title":"Thromboembolic risk in inflammatory neuromuscular disease patients on long-term IVIg","volume":"27","author":"Spillane","year":"2017","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.neurol.2020.04.029_bib0360","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1212\/01.WNL.0000068335.01620.9D","article-title":"The clinical features of 16 cases of stroke associated with administration of IVIg","volume":"60","author":"Caress","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2020.04.029_bib0365","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1111\/trf.12897","article-title":"Intravenous immunoglobulin-associated thrombosis: is it such a rare event? Report of a pediatric case and of the Quebec Hemovigilance System","volume":"55","author":"Benadiba","year":"2015","journal-title":"Transfusion (Paris)"},{"key":"10.1016\/j.neurol.2020.04.029_bib0370","doi-asserted-by":"crossref","first-page":"e689","DOI":"10.1097\/MJT.0000000000000373","article-title":"Immune Modulatory Therapy Causing Acute Coronary Syndrome","volume":"24","author":"Agrawal","year":"2017","journal-title":"Am J Ther"},{"key":"10.1016\/j.neurol.2020.04.029_bib0375","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/S0002-9394(14)70844-X","article-title":"Iatrogenic central retinal vein occlusion and hyperviscosity associated with high-dose intravenous immunoglobulin administration","volume":"124","author":"Oh","year":"1997","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.neurol.2020.04.029_bib0380","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1097\/01.SMJ.0000105663.01648.25","article-title":"Virchow's triad revisited","volume":"97","author":"Brotman","year":"2004","journal-title":"South Med J"}],"container-title":["Revue Neurologique"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0035378720306111?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0035378720306111?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T05:40:13Z","timestamp":1758519613000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0035378720306111"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":38,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["S0035378720306111"],"URL":"https:\/\/doi.org\/10.1016\/j.neurol.2020.04.029","relation":{},"ISSN":["0035-3787"],"issn-type":[{"value":"0035-3787","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Should we prevent thrombosis related to intravenous immunoglobulin infusions with systematic anticoagulant prophylaxis?","name":"articletitle","label":"Article Title"},{"value":"Revue Neurologique","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neurol.2020.04.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}